Pimodivir

Generic Name: Pimodivir

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₁₉F_₂N_₅O_₂

CAS Number: 1629869-44-8

Unique Ingredient Identifier: DFC121MXC3

Background: Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment

Phase 1

Terminated

Conditions: Kidney Failure, Chronic

Interventions: Drug: Pimodivir

First Posted Date: 2019-05-13

Last Posted Date: 2022-07-05

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 29

Registration Number: NCT03947814

Locations: 🇩🇪
APEX GmbH, Munchen, Germany
🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

Conditions: H7N9 Subtype of Influenza A Virus

First Posted Date: 2019-02-08

Last Posted Date: 2020-10-28

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT03834376

A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Pimodivir

First Posted Date: 2019-01-25

Last Posted Date: 2020-07-08

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 42

Registration Number: NCT03816631

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪
APEX GmbH, Munchen, Germany

A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pimodivir
Drug: Cyclosporine

First Posted Date: 2018-12-07

Last Posted Date: 2019-04-29

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 18

Registration Number: NCT03768609

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-63623872
Drug: Oseltamivir

First Posted Date: 2017-01-18

Last Posted Date: 2017-05-25

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 45

Registration Number: NCT03023852

Locations: 🇧🇪
SGS Life Science Services, Antwerp, Belgium

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Phase 1

Completed

Conditions: Influenza in Humans

Interventions: Drug: AL-794
Drug: Pitavastatin
Drug: JNJ-63623872
Drug: Digoxin
Drug: Oseltamivir
Drug: Midazolam

First Posted Date: 2016-09-05

Last Posted Date: 2018-06-25

Lead Sponsor: Alios Biopharma Inc.

Target Recruit Count: 68

Registration Number: NCT02888327

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom

Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-63623872
Drug: Placebo

First Posted Date: 2016-08-09

Last Posted Date: 2018-01-30

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 66

Registration Number: NCT02860806

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-63623872 2400 milligram (mg)
Drug: JNJ-63623872 3000 mg
Drug: JNJ-63623872
Drug: Placebo (Matching with JNJ-63623872 2400 mg)
Drug: Placebo (Matching with JNJ-63623872 3000 mg)
Drug: Moxifloxacin
Drug: Placebo (Matching with JNJ-63623872 Dose)
Drug: Placebo (Matching with Moxifloxacin)

First Posted Date: 2016-01-20

Last Posted Date: 2016-06-17

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 66

Registration Number: NCT02658825

A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ethinylestradiol
Drug: Norethindrone
Drug: JNJ-63623872

First Posted Date: 2016-01-12

Last Posted Date: 2016-06-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT02652650

A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pitavastatin
Drug: JNJ-63623872

First Posted Date: 2015-11-03

Last Posted Date: 2016-01-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14

Registration Number: NCT02595268

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy